Cargando…

CD47 expression is decreased in hematopoietic progenitor cells in patients with myelofibrosis

Myelofibrosis (MF) is characterized by increased circulating hematopoietic progenitor cells (HPCs), abnormal cytokine levels, and the survival advantage of neoplastic progenitors over their normal counterparts, which leads to progressive disappearance of polyclonal hematopoiesis. CD47 is a surface g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nonino, A., Nascimento, J.M., Mascarenhas, C.C., Mazzeu, J.F., Pereira, R.W., Jacomo, R.H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Associação Brasileira de Divulgação Científica 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301265/ https://www.ncbi.nlm.nih.gov/pubmed/30539968 http://dx.doi.org/10.1590/1414-431X20187784

Ejemplares similares

Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis
por: Varricchio, Lilian, et al.
Publicado: (2022)

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis
por: Farina, Mirko, et al.
Publicado: (2021)

Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells
por: Lu, Min, et al.
Publicado: (2021)

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
por: Zhang, Lining, et al.
Publicado: (2020)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

Next Generation Therapeutics for the Treatment of Myelofibrosis
por: Tremblay, Douglas, et al.
Publicado: (2021)

The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis
por: Wolfe, Heather R., et al.
Publicado: (2022)

E-Cigarette Exposure Decreases Bone Marrow Hematopoietic Progenitor Cells
por: Ramanathan, Gajalakshmi, et al.
Publicado: (2020)

TGF-β signaling in myeloproliferative neoplasms contributes to myelofibrosis without disrupting the hematopoietic niche
por: Yao, Juo-Chin, et al.
Publicado: (2022)

Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies
por: Naymagon, Leonard, et al.
Publicado: (2017)

miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6
por: Rontauroli, Sebastiano, et al.
Publicado: (2017)

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

Epidemiology and Treatment of Acute Promyelocytic Leukemia in Latin America
por: Rego, E.M., et al.
Publicado: (2011)

Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis
por: Bianchi, Elisa, et al.
Publicado: (2017)

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
por: Gagelmann, Nico, et al.
Publicado: (2022)

Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis
por: Perram, Jacinta, et al.
Publicado: (2022)

Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes
por: Jungius, Sarah, et al.
Publicado: (2023)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Methylome of human senescent hematopoietic progenitors
por: Capone, Stephen, et al.
Publicado: (2018)

Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
por: Murthy, Guru Subramanian Guru, et al.
Publicado: (2023)

PB2230: THE ORIGIN IN PRIMARY AND SECONDARY MYELOFIBROSIS: IS THE KEY THE PROGENITOR OR THE MOLECULAR SIGNATURE?
por: Cuadrado, Isabel Montero
Publicado: (2023)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Biological drivers of clinical phenotype in myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2022)

Arsenite exposure inhibits the erythroid differentiation of human hematopoietic progenitor CD34(+) cells and causes decreased levels of hemoglobin
por: Wan, Guanghua, et al.
Publicado: (2021)

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
por: Harrison, C., et al.
Publicado: (2022)

Myelofibrosis
por: Passamonti, Francesco, et al.
Publicado: (2023)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
por: Harrison, C., et al.
Publicado: (2022)

Haploidentical hematopoietic stem cell transplantation in a myelofibrosis patient with primary graft failure
por: Tecchio, Cristina, et al.
Publicado: (2018)

Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
por: Gagelmann, Nico, et al.
Publicado: (2023)

The tale of two organs: allogeneic hematopoietic stem cell transplantation following liver transplantation in a myelofibrosis patient
por: Bastin, Donald J., et al.
Publicado: (2023)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
por: Tremblay, Douglas, et al.
Publicado: (2023)

Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis
por: Leimkühler, Nils B., et al.
Publicado: (2021)

Exercise-Induced Norepinephrine Decreases Circulating Hematopoietic Stem and Progenitor Cell Colony-Forming Capacity
por: Kröpfl, Julia M., et al.
Publicado: (2014)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Cd44 Is a Major E-Selectin Ligand on Human Hematopoietic Progenitor Cells
por: Dimitroff, Charles J., et al.
Publicado: (2001)

BCL2A1a Over-Expression in Murine Hematopoietic Stem and Progenitor Cells Decreases Apoptosis and Results in Hematopoietic Transformation
por: Métais, Jean-Yves, et al.
Publicado: (2012)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
por: Xu, Z., et al.
Publicado: (2022)

Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cells
por: Serafini, Marta, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_q9ql47145cf1ujbqd565djc5nl